MA29940B1 - Composes utiles en therapie - Google Patents
Composes utiles en therapieInfo
- Publication number
- MA29940B1 MA29940B1 MA30910A MA30910A MA29940B1 MA 29940 B1 MA29940 B1 MA 29940B1 MA 30910 A MA30910 A MA 30910A MA 30910 A MA30910 A MA 30910A MA 29940 B1 MA29940 B1 MA 29940B1
- Authority
- MA
- Morocco
- Prior art keywords
- 6alkyl
- therapy
- aryl
- halogen
- compounds useful
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000000450 Pelvic Pain Diseases 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 208000005641 Adenomyosis Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000001791 Leiomyomatosis Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 201000009274 endometriosis of uterus Diseases 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS DE FORMULE (1) OU UN DÉRIVÉ PHARMACEUTIQUEMENT ACCEPTABLE DE CES COMPOSÉS, OÙ R1 ET R3 REPRÉSENTENT INDÉPENDAMMENT H, C1-6ALKYL, C3-8CYCLOALKYL, OU DE L'HALOGÈNE; R2 REPRÉSENTE C1-6ALKYL, CF3 OU DE L'ARYLE, A REPRÉSENTE 1 OU 2; R4, R5, R7 ET R8 REPRÉSENTENT INDÉPENDAMMENT H, C1-6ALKYL, C1-6ALKYLOXY, CN OU DU HALOGÈNE, OU R4 ET R5, OU R7 ET R8, ENSEMBLE AVEC L'ANNEAU AUQUEL ILS SONT ATTACHÉS FORMENT UN ARYLE OU UN SYSTÈME D'ANNEAU FUSIONNÉ HÉTÉROCLYCIQUE, X REPRÉSENTE C OU N, Y REPRÉSENTE CH2 OU O, R6 REPRÉSENTE H, CN OU UN HALO, MAIS LORSQUE X REPRÉSENTE N, ALORS R6 REPRÉSENTE H; CELA PEUT ÊTRE UTILE POUR TRAITER L'ENDOMÉTRIOSE, LES FIBROMES UTÉRINS (LÉIOMYOMATOSE), LA MÉNORRAGIE, L'ADÉNOMYOSE, LA DYSCHEXIE ET LA DOULEUR PELVIQUE CHRONIQUE) OU LE SYNDROME DE DOULEUR PELVIQUE CHRONIQUE.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73509105P | 2005-11-08 | 2005-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29940B1 true MA29940B1 (fr) | 2008-11-03 |
Family
ID=37909834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30910A MA29940B1 (fr) | 2005-11-08 | 2008-05-08 | Composes utiles en therapie |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US7309712B2 (fr) |
| EP (1) | EP1948615B1 (fr) |
| JP (1) | JP4234786B1 (fr) |
| KR (1) | KR100997595B1 (fr) |
| CN (1) | CN101304974A (fr) |
| AP (1) | AP2008004463A0 (fr) |
| AR (1) | AR056780A1 (fr) |
| AT (1) | ATE537150T1 (fr) |
| AU (1) | AU2006313478A1 (fr) |
| BR (1) | BRPI0618630A2 (fr) |
| CA (1) | CA2628844C (fr) |
| CR (1) | CR9959A (fr) |
| CY (1) | CY1112286T1 (fr) |
| DK (1) | DK1948615T3 (fr) |
| DO (1) | DOP2006000245A (fr) |
| EA (1) | EA014693B1 (fr) |
| EC (1) | ECSP088431A (fr) |
| ES (1) | ES2376252T3 (fr) |
| GT (1) | GT200600478A (fr) |
| HN (1) | HN2006037713A (fr) |
| IL (1) | IL190806A0 (fr) |
| MA (1) | MA29940B1 (fr) |
| NL (1) | NL2000299C2 (fr) |
| NO (1) | NO20082504L (fr) |
| PE (1) | PE20070642A1 (fr) |
| PL (1) | PL1948615T3 (fr) |
| PT (1) | PT1948615E (fr) |
| RS (1) | RS20080191A (fr) |
| SI (1) | SI1948615T1 (fr) |
| TN (1) | TNSN08202A1 (fr) |
| TW (1) | TWI321563B (fr) |
| UA (1) | UA90763C2 (fr) |
| UY (1) | UY29904A1 (fr) |
| WO (1) | WO2007054770A2 (fr) |
| ZA (1) | ZA200803670B (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL126999A (en) | 1996-07-24 | 2002-03-10 | Warner Lambert Co | Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain |
| JP4234786B1 (ja) * | 2005-11-08 | 2009-03-04 | ファイザー・リミテッド | ピラゾール誘導体およびその医学的使用 |
| EP2081905B1 (fr) | 2006-07-28 | 2012-09-12 | Boehringer Ingelheim International GmbH | Composés sulfonyles modulant le récepteur cb2 |
| CA2664310A1 (fr) | 2006-09-25 | 2008-04-03 | Boehringer Ingelheim International Gmbh | Composes modulant le recepteur cb2 |
| WO2008135824A1 (fr) * | 2007-05-02 | 2008-11-13 | Pfizer Limited | Composés d'oxyalkylpyrazole utiles en thérapie |
| JP5492092B2 (ja) | 2007-11-07 | 2014-05-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節する化合物 |
| JP2010043063A (ja) * | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | 川崎病の診断及び治療 |
| EP2418207A1 (fr) * | 2008-05-13 | 2012-02-15 | Boehringer Ingelheim International GmbH | Composés de sulfone qui modulent le récepteur CB2 |
| EP2326629B1 (fr) | 2008-07-10 | 2013-10-02 | Boehringer Ingelheim International GmbH | Composés sulfones qui modulent le récepteur cb2 |
| WO2010036630A2 (fr) | 2008-09-25 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Composés modulant sélectivement le récepteur cb2 |
| US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| JP5756800B2 (ja) | 2009-06-16 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体 |
| JP2013505295A (ja) | 2009-09-22 | 2013-02-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を選択的に調節する化合物 |
| US10610528B2 (en) | 2009-12-08 | 2020-04-07 | Intelgenx Corp. | Solid oral film dosage forms and methods for making same |
| US20110136815A1 (en) | 2009-12-08 | 2011-06-09 | Horst Zerbe | Solid oral film dosage forms and methods for making same |
| US9315454B2 (en) | 2010-01-15 | 2016-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
| EP2542539B1 (fr) | 2010-03-05 | 2014-02-26 | Boehringer Ingelheim International GmbH | Composés tétrazoles qui modulent sélectivement le récepteur cb2 |
| US20110263606A1 (en) * | 2010-04-26 | 2011-10-27 | Horst Zerbe | Solid oral dosage forms comprising tadalafil |
| JP5746764B2 (ja) | 2010-07-22 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節する化合物 |
| EP2803668A1 (fr) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles |
| TWI902102B (zh) * | 2017-04-06 | 2025-10-21 | 美商富曼西公司 | 殺真菌之噁二唑 |
| JP2022504982A (ja) * | 2018-10-18 | 2022-01-13 | 南京聖和薬業股▲ふん▼有限公司 | ＴＧＦ－βＲ１阻害剤としての化合物及びその応用 |
| RU2711615C1 (ru) * | 2019-09-12 | 2020-01-17 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" | Способ лечения эндометриоза на основании экспериментальной модели у крыс |
| CN111269097B (zh) * | 2020-04-02 | 2023-02-17 | 苏州爱玛特生物科技有限公司 | 一种多元环双取代的1,3-丙二酮类化合物的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6281638A (ja) * | 1985-10-07 | 1987-04-15 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料 |
| JPS63313784A (ja) * | 1987-03-12 | 1988-12-21 | Zeria Shinyaku Kogyo Kk | 新規ピラゾール誘導体およびその製造法ならびにこれを有効成分とする抗潰瘍剤 |
| DE4414792A1 (de) * | 1993-08-11 | 1995-02-16 | Bayer Ag | Arzneimittel enthaltend 1-Thiocarbamoyl-5-hydroxypyrazolen und deren Verwendung als Mittel zur Bekämpfung des septischen Schocks |
| RS51166B (sr) * | 2001-04-10 | 2010-10-31 | Pfizer Inc. | Derivati pirazola za tretiranje hiv |
| GB0229618D0 (en) * | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
| JP4234786B1 (ja) * | 2005-11-08 | 2009-03-04 | ファイザー・リミテッド | ピラゾール誘導体およびその医学的使用 |
-
2006
- 2006-10-26 JP JP2008539519A patent/JP4234786B1/ja not_active Expired - Fee Related
- 2006-10-26 AP AP2008004463A patent/AP2008004463A0/xx unknown
- 2006-10-26 AU AU2006313478A patent/AU2006313478A1/en not_active Abandoned
- 2006-10-26 RS RSP-2008/0191A patent/RS20080191A/sr unknown
- 2006-10-26 CA CA2628844A patent/CA2628844C/fr not_active Expired - Fee Related
- 2006-10-26 KR KR1020087010982A patent/KR100997595B1/ko not_active Expired - Fee Related
- 2006-10-26 DK DK06809167.7T patent/DK1948615T3/da active
- 2006-10-26 ES ES06809167T patent/ES2376252T3/es active Active
- 2006-10-26 CN CNA2006800416684A patent/CN101304974A/zh active Pending
- 2006-10-26 UA UAA200805973A patent/UA90763C2/ru unknown
- 2006-10-26 WO PCT/IB2006/003080 patent/WO2007054770A2/fr not_active Ceased
- 2006-10-26 SI SI200631237T patent/SI1948615T1/sl unknown
- 2006-10-26 EA EA200801053A patent/EA014693B1/ru not_active IP Right Cessation
- 2006-10-26 BR BRPI0618630-0A patent/BRPI0618630A2/pt not_active IP Right Cessation
- 2006-10-26 AT AT06809167T patent/ATE537150T1/de active
- 2006-10-26 PT PT06809167T patent/PT1948615E/pt unknown
- 2006-10-26 EP EP06809167A patent/EP1948615B1/fr active Active
- 2006-10-26 PL PL06809167T patent/PL1948615T3/pl unknown
- 2006-11-02 NL NL2000299A patent/NL2000299C2/nl not_active IP Right Cessation
- 2006-11-03 US US11/592,574 patent/US7309712B2/en not_active Expired - Fee Related
- 2006-11-06 PE PE2006001366A patent/PE20070642A1/es not_active Application Discontinuation
- 2006-11-07 GT GT200600478A patent/GT200600478A/es unknown
- 2006-11-07 TW TW095141158A patent/TWI321563B/zh active
- 2006-11-07 HN HN2006037713A patent/HN2006037713A/es unknown
- 2006-11-07 AR ARP060104881A patent/AR056780A1/es unknown
- 2006-11-08 UY UY29904A patent/UY29904A1/es not_active Application Discontinuation
- 2006-11-08 DO DO2006000245A patent/DOP2006000245A/es unknown
-
2007
- 2007-10-11 US US11/870,451 patent/US7425569B2/en not_active Expired - Fee Related
-
2008
- 2008-04-10 IL IL190806A patent/IL190806A0/en unknown
- 2008-04-25 ZA ZA200803670A patent/ZA200803670B/xx unknown
- 2008-05-06 EC EC2008008431A patent/ECSP088431A/es unknown
- 2008-05-07 TN TNP2008000202A patent/TNSN08202A1/fr unknown
- 2008-05-08 CR CR9959A patent/CR9959A/es not_active Application Discontinuation
- 2008-05-08 MA MA30910A patent/MA29940B1/fr unknown
- 2008-06-05 NO NO20082504A patent/NO20082504L/no not_active Application Discontinuation
-
2012
- 2012-01-27 CY CY20121100096T patent/CY1112286T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29940B1 (fr) | Composes utiles en therapie | |
| MX2010005717A (es) | Derivados de isoxazolo-piridina. | |
| WO2004026248A3 (fr) | Derives d'octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide en tant que modulateurs selectifs de recepteur glucocorticoide | |
| ATE496620T1 (de) | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren | |
| DK1606242T3 (da) | Azidfri fremgangsmåde til fremstilling af 1,2-diaminoforbindelser | |
| DE69820632D1 (de) | 2-phenyl-substituierte 1-(n-phenylaminoalkyl)-piperazin-derivate | |
| CY1108455T1 (el) | Νεος στεροειδης αγωνιστης δια fxr | |
| EA200500814A1 (ru) | Производные пирролопиримидина | |
| WO2007012661A8 (fr) | Composes derives d'hydantoïne et leur utilisation en tant qu'antagonistes de mchr-1 | |
| WO2002003988A3 (fr) | Methodes permettant de traiter de troubles associes au neuropeptide y - | |
| ATE446962T1 (de) | Thiazolopyridinon-derivate als mch- rezeptorantagonisten | |
| ATE414516T1 (de) | Morphinanderivate als mittel gegen juckreiz | |
| WO2006038006A3 (fr) | Nouveaux composes | |
| EP1617806A4 (fr) | Modulateurs des recepteurs aux glucocorticoides spirocycliques selectifs | |
| EE200100520A (et) | N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena | |
| ATE466842T1 (de) | 3-substituierte pyridinderivate als h3- antagonisten | |
| DE602006010540D1 (de) | (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl)-amine mit aktivität am 5-ht-rezeptor | |
| HK1049486A1 (zh) | 作為mcp-1受體拮抗劑的吲類衍生物 | |
| ATE466007T1 (de) | 5-substituierte indol-2-carbonsäureamidderivate | |
| ATE488236T1 (de) | Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen | |
| EA200300850A1 (ru) | Применение антагонистов рецептора gal3 при лечении депрессии и/или тревоги и соединения, полезные в таких способах | |
| WO2006134486A3 (fr) | Composes alpha-(aryl-ou heteroaryl-methyl)-beta piperidino propanamide utiles en tant qu'antagonistes du recepteur orl1 | |
| ATE545627T1 (de) | Glattmuskelspasmolytika | |
| DE60137451D1 (de) | N-substituierte Amide als NK1 Rezeptor Antagonisten | |
| TW200621234A (en) | Preventive or remedy for urinary storage dysfunction accompanied by disorders associated with the lower urinary tract obstruction |